KCNK3
MOLECULAR TARGETpotassium two pore domain channel subfamily K member 3
KCNK3 (potassium two pore domain channel subfamily K member 3) is targeted by 9 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).
Compounds Targeting KCNK3
Ranked by bioassay confidence score (PubChem active assay count × evidence quality).
| # | Compound | Confidence | Active Assays |
|---|---|---|---|
| 1 | auraptene | 1.10 | 2 |
| 2 | Clotrimazole | 1.10 | 2 |
| 3 | Arachidonic Acid | 0.69 | 1 |
| 4 | 17 alpha-Hydroxyprogesterone Caproate Hydroxyprogesterone derivative that acts as | 0.69 | 1 |
| 5 | Bisphenol A-Glycidyl Methacrylate | 0.69 | 1 |
| 6 | Fluoxymesterone | 0.69 | 1 |
| 7 | Miconazole | 0.69 | 1 |
| 8 | Oxyphenbutazone | 0.69 | 1 |
| 9 | Testosterone Propionate | 0.69 | 1 |
About KCNK3 as a Drug Target
KCNK3 (potassium two pore domain channel subfamily K member 3) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 9 compounds with documented KCNK3 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.
KCNK3 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.